Tumor-related glycoprotein or glycan antigen alterations approved by the Food and Drug Administration (FDA), such as core fucosylated AFP (AFP-L3), are better targets for tumor diagnosis and prognosis than AFP alone (24). Here, AFP is linked to neoplasm.